Brief: AlloVir Reports Full-Year 2021 Financial Results And 2022 Outlook

Kalaris Therapeutics

10/02/2022 12:32

Feb 10 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR REPORTS FULL-YEAR 2021 FINANCIAL RESULTS AND 2022
OUTLOOK
    * ALLOVIR INC - ENROLLMENT OF HC TRIAL IS EXPECTED TO BE
COMPLETE
IN FIRST HALF OF 2023
    * ALLOVIR INC - FOR 2022, ALLOVIR EXPECTS OPERATING EXPENSES
TO BE
IN RANGE OF $130 MILLION TO $145 MILLION, EXCLUDING NON-CASH
STOCK COMPENSATION EXPENSES

Source text for Eikon:  ID:nBw7c69MDa 
Further company coverage:  ALVR.O 

 ((Reuters.Briefs@thomsonreuters.com;))